AbbVie Becomes An Overnight Oncology Force With Pharmacyclics
This article was originally published in The Pink Sheet Daily
Executive Summary
The company outbid two rivals to win Pharmacyclics and its fast-growing cancer drug Imbruvica in an expensive acquisition that will cost AbbVie about $21 billion. But the fact that Pharmacyclics shares sales and profits on Imbruvica with J&J may leave some investors questioning the high premium.
You may also be interested in...
Stockwatch: Repeating Past Mistakes At AbbVie
AbbVie’s latest, largest acquisition may be cast in a new light as the pandemic throws stock markets into turmoil and commercial prospects up in the air.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.